�BioSphere Medical, Inc. (NASDAQ:BSMD) - a medical twist company that has pioneered the purpose of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today announced that in its August Practice Bulletin, the American College of Obstetricians and Gynecologists (ACOG) recommended uterine artery embolization (UAE) (also known as UFE) as an alternate to hysterectomy in the management of leiomyomas (fibroids). The bulletin cites the availability of Level A research, which is based on "safe and logical scientific evidence" that shows that UAE "is a safe and effective option for befittingly selected women who wish to keep their uteri." The passport is likewise based on both retentive and short-term treatment outcomes.
"We are pleased UFE has obtained this crucial recognition, and believe it is a significant stride in the ongoing exploitation of the market for this minimally invasive, uterus-sparing alternative to hysterectomy," commented Richard J. Faleschini, president and CEO of BioSphere Medical. Mr. Faleschini continued, "Gynecologists ar one of the key providers in women's health. We think the new guidelines in this Practice Bulletin should result in more gynecologists discussing UFE as a mainstream handling option with their patients and forging collaborative relationships with interventional radiologists to optimize the quality of care offered to women with fibroids."
About BioSphere Medical, Inc.
BioSphere Medical, Inc. seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are put-upon to acquire microscopic globose materials with unique beneficial properties for a sort of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a operation called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as advantageously as in a number of other new and established medical treatments. http://www.biospheremed.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the expected favorable benefits of the ACOG Practice Bulletin on gynecologists' treatment and referral behaviors. The Company may use words such as "plans," "seeks," "projects," "believes," "may," "anticipates," "estimates," "should," "intends," "looking ahead," and similar expressions to identify these forward-looking statements. There ar a identification number of significant factors that may affect the Company's actual public presentation and results and the accuracy of its advanced statements, many of which are beyond the Company's control and are difficult to predict. These important factors include, without limitation, risks relating to: the failure of the Company to successfully develop, commercialize and attain widespread mart acceptance of its products; the failure of the Company to increase the rate of UFE procedures, and co-occurrence use of its products for UFE, with its expanded gross sales force and its of late initiated gross sales and selling strategies; the failure of the Company to attain or maintain necessary regulative approvals; the Company's power to obtain and sustain patent and other proprietary protection; the absence of, or delays or cancellations of, mathematical product orders, and delays, difficulties or unlooked-for costs in the creation of new products; private-enterprise pressures and the danger of product liability claims, either of which may impact grocery acceptance of products and adversely involve the Company's operating results; the inability of the Company to successfully execute on its plans and strategies for future increase; the unfitness of the Company to raise extra funds in the good term to finance the development, marketing, and gross sales of its products; general economic and market conditions, both domestically and abroad; and risk of exposure factors described in the section coroneted "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter complete June 30, 2008, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's estimates as of the date of this spillage. The Company anticipates that subsequent events and developments may crusade its innovative statements to change. The Company specifically disclaims whatever obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances after the date of this push release.
More info
